Aradhana Sarin: Sure. Yes. So obviously, we’ve updated our guidance for the full year. And given our third quarter results, I think you can extrapolate where the range would be for the fourth quarter. We’ve also said that the higher end of that range is very much dependent on couple of the factors that we mentioned, the delivery of Evusheld, which, again, is variable. We’re waiting for the approval of PROpel both in the U.S and Europe and that would trigger certain milestones, as you know, as part of our collaboration. And then yes, there is expected some impact from the VBP and NRDL and we’ll know by end of this month, where the pricing falls for as part of those agreements, and therefore what the stock compensation impact will be in the fourth quarter. So I think we’ve given you enough for you to be able to triangulate that. Susan?
Susan Galbraith: Yes, sure. So just in terms of the potential for Tagrisso combinations, obviously, the study which we anticipate reading out, will give us the answer about the combination benefit of a chemotherapy plus an EGFR inhibitor in the first-line. Based on the Opal that we presented at ASCO, we’re confident about the potential profile that we’ve got there. We’re also exploring combinations with Dato-DXd in the ORCHARD study with Tagrisso. And if that looks promising, that is a potential to go into the to the first-line. And obviously, that’s a nearer term potential than our AZD9592 where we’ve just filed the IND and anticipate starting Phase I later this year or early next year. I think in terms of answering your question about the place for a bi-specific EGFR met.
Obviously, for is a naked antibody that’s designed to overcome resistance to EGFR signaling inhibition. In that setting, you’re looking at met amplification, which is a subset and a small subset of first-line EGFR mutant lung cancer. In this case, what we’re looking at is the co-expression of EGFR and met as a hook on the surface to deliver the antibody drug conjugate. So it’s a different mechanism in that regard. And in that setting, what you’re looking for is that co-expression of met and EGFR which is more common, not just in EGFR mutant lung cancer, but also across EGFR wild type, and also in colorectal cancer and other settings. So I think the potential development plan for AZD9592 is much wider than just EGFR mutant lung cancer
Pascal Soriot: It goes beyond lung cancer, for sure, yes. And that’s really a big opportunity, potentially. Next one is Richard Parkes at Exane.
Richard Parkes: Hi. Thanks for taking my questions. First one, I just wanted to push Susan a little a bit more on the camizestrant data ahead of the presentation. What we’ve seen in with other compounds is that the benefits in that setting have been almost solely driven by benefit in patients with the mutant mutations. And I just wondered whether you’d seen the same thing in SERENA-2, or have you seen broader activity. So whether you could talk about that consistency. Then secondly, just on margin progression in 2023, you talked about FX being an uncertainty. So it sounds like that could be a drag to margins in 2023. I wonder if you could quantify what that would look like based on current spot rates. And then just on margins, also, you have an ongoing operational efficiency program, which I think you’d said would deliver over $1 billion in savings. I just wonder how much that will benefit 2023 to enable reinvestment? Thank you.
Pascal Soriot: Thank you. Do you want to take the first one?
